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Abstract
Background: Little is known about short-term bacterial fluctuations in the human vagina. This study used PCR to assess the
variability in concentrations of key vaginal bacteria in healthy women and the immediate response to antibiotic treatment
in women with bacterial vaginosis (BV).
Methodology/Principal Findings: Twenty-two women assessed for BV using Amsel’s criteria were evaluated daily for 7 or
14 days, then at 2, 3 and 4 weeks, using a panel of 11 bacterium-specific quantitative PCR assays. Participants with BV were
treated with 5 days of intravaginal metronidazole. Participants without BV had vaginal biotas dominated by lactobacilli,
whose levels fluctuated with menses. With onset of menstruation, quantities of Lactobacillus jensenii and Lactobacillus
crispatus decreased and were found to be inversely related to Gardnerella vaginalis concentrations (p,0.001). Women with
BV had a variety of fastidious bacteria whose concentrations dropped below detection thresholds 1–5 days after starting
metronidazole. Recurrent BV was characterized by initial profound decreases of BV-associated bacteria after treatment
followed by subsequent increases at relapse.
Conclusions/Significance: The microbiota of the human vagina can be highly dynamic. Healthy women are colonized with
Lactobacillus species, but levels can change dramatically over a month. Marked increases in G. vaginalis were observed
during menses. Participants with BV have diverse communities of fastidious bacteria that are depleted by vaginal
metronidazole therapy. Women with recurrent BV initially respond to antibiotic treatment with steep declines in bacterial
concentrations, but these bacteria later reemerge, suggesting that antibiotic resistance in these bacteria is not an important
factor mediating BV recurrence.
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Introduction
The human vagina hosts communities of microbes that can
impact the health of women and their neonates. Bacterial
vaginosis (BV) is a common condition, affecting ,29% of
reproductive age women in the USA [1] and is associated with
an increase in the risk for pre-term birth [2], HIV-1 acquisition [3]
and pelvic inflammatory disease [4]. The pathogenesis of BV is
poorly understood. BV is associated with loss of vaginal lactobacilli
such as Lactobacillus crispatus and Lactobacillus jensenii, and acquisition
of complex communities of anaerobic bacteria. Although the
vaginal bacterial biota has been intensively investigated using
cultivation (reviewed in [5,6]) and molecular approaches (reviewed
in [7]), few studies have measured short-term fluctuations in the
vaginal microbiota using cultivation-independent methods. Persis-
tent or relapsing BV is a common problem with relapse rates
greater than 50% within 6 months of treatment [8]. Taxon-
directed quantitative PCR (qPCR) has been used to measure levels
of key vaginal bacteria and how they change after antibiotic
treatment in women with cured and persistent BV [9], but that
study did not measure immediate responses to antibiotic
treatment. It is unknown whether bacterial eradication was ever
achieved, particularly in women with persistent BV. This raises the
question of whether the bacteria are non-responsive to antibiotic
treatment in women with recurrent BV, or whether the bacteria
are eradicated but return with re-inoculation. If the latter situation
is most relevant, when and how women with recurrent BV are re-
infected is not clear. Longitudinal studies with frequent sampling
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ing these questions. Furthermore, the degree of stability of the
vaginal bacterial community in women without BV in not well
understood. How dynamic is the vaginal microbiota and are BV-
associated bacteria detected in women without BV at low
concentrations? We sought to address these questions by
evaluating key vaginal bacterial levels from samples collected
longitudinally from healthy women and women with BV using a
panel of taxon-specific bacterial qPCR assays.
Materials and Methods
Study population, clinical evaluation and sample
collection
Thirty-three subjects were recruited for this longitudinal study
from the Public Health - Seattle and King County Sexually
Transmitted Diseases Clinic (STD clinic) between September
2006 and May 2009. The study was approved by the Institutional
Review Board at the Fred Hutchinson Cancer Research Center.
Written informed consent was obtained from all study partici-
pants. Participants were evaluated in clinic on Day 0 (recruitment),
and returned to clinic for examination at 1 month (25–49 days;
Median=28). All participants were asked to self-collect vaginal
swabs daily for 7 or 14 days, then at 2 weeks and 3 weeks. Self-
collected swabs were mailed in on the day of collection at room
temperature and held at 280uC before processing. In twelve
additional participants, swabs were also collected at 2, 3 and 4
months after study entry. If participants were diagnosed with BV
at 4 months, they were offered to re-enroll in the study, facilitating
the observation of women with recurrent BV.
At clinic visits, participants were interviewed regarding medical
history and sexual behaviors, and underwent a standard physical
examination including a pelvic exam with speculum for collection
of samples. At the enrollment visit, swabs of vaginal fluid samples
were collected for Gram staining, pH, saline microscopy and
KOH preparation. Samples for DNA extraction and PCR were
obtained using polyurethane foam swabs (Epicenter Biotechnolo-
gies, Madison, WI) that were brushed against the lateral vaginal
wall, re-sheathed and frozen immediately at 220uC and
subsequently held at 280uC. At clinic visits, BV was diagnosed
using Amsel’s clinical criteria [10] and vaginal fluid smears were
collected for Gram stains by the Nugent method [11] to confirm
the presence of BV. Subjects with BV, diagnosed using Amsel’s
clinical criteria, were treated with 5 g 0.75% intravaginal
metronidazole gel used each night for 5 days. Testing for STDs
and other vaginal infections was performed as previously described
[9]. A daily diary was maintained by the participants where they
recorded menstruation, medication use and symptoms.
DNA extraction and quality control
DNA was extracted using the Ultra Clean Soil DNA Kit
(Mobio, Carlsbad, CA) [12], eluted in 150 ml buffer and diluted
1:1 in 1 mM Tris, 0.1 mM EDTA buffer. Two ml of the diluted
DNA was used in each qPCR assay. Sham digests from swabs
without human contact assessed contamination from reagents or
collection swabs. Human 18S rRNA gene qPCR measured human
DNA levels verifying that the swab contacted a human tissue
surface and documenting successful extraction [13]. All DNA
samples were tested for PCR inhibition using a sensitive qPCR
approach targeting a segment of exogenously added jellyfish DNA
at a concentration suitable for detection of low levels of inhibitors
[13]. Inhibition was defined as a delay in the threshold cycle by
$2 cycles compared to the no-DNA-template controls.
Quantitative PCR
Eleven qPCR assays targeting key vaginal bacteria associated
with health or BV were applied to the samples. Assays for the
detection of Gardnerella vaginalis, Lactobacillus crispatus, Megasphaera-
like bacterium (type 1 & type 2), Atopobium vaginae, Leptotrichia and
Sneathia species (single assay) and three Clostridiales Order bacteria
designated as bacterial vaginosis associated bacterium 1 (BVAB1),
BVAB2 and BVAB3 were applied as described previously [9]. We
developed three additional assays targeting Lactobacillus jensenii,
Lactobacillus iners, and a combined assay for Mobiluncus curtisii and
Mobiluncus mulieris using a probe-based assay format [9] with 16S
rRNA gene-specific primers, and a taxon-directed hydrolysis
probe. Core reagents were from Applied Biosystems (Carlsbad,
CA) and master mixes contained buffer A (1 mM), deoxynucle-
otide triphosphates (1 mM), magnesium (3 mM), AmpErase
uracil-N-glycosylase (0.05 U) and AmpliTaq Gold polymerase
(1–1.5 U) per reaction. Primers were added at 0.8 mM per
reaction (Mobiluncus assay-1.2 mM forward primer) and final probe
concentration was 150 mM. Assays underwent 45 cycles of
amplification on the Eppendorf Mastercycler realplex Thermal
cycler (Hamburg, Germany). Specificity and sensitivity were
defined as described previously [9]. Plasmid standards were run
in duplicate from 10
6 to 2.5 copies, and values are reported as 16S
rRNA gene copies/swab. Assay details are provided in Table 1.
Statistics
To determine differences in DNA recovery in clinic-collected
versus self-collected swabs, we used the Wilcoxon signed rank test
to compare paired medians of the quantities of human 18S rRNA
gene copies, G. vaginalis, L. jensenii and L. crispatus from 14 women
without BV, obtained within one day of each other. To examine
apparent patterns in levels of bacteria relative to menstruation,
mean differences in log10 quantities of bacteria during menstru-
ation were estimated using a linear mixed model, adjusting for
treatment and with subjects as random effects to account for
correlation in repeated measurements on each subject. Bacterial
levels, when not detected, were considered to be half the detection
limit.
Results
Subject characteristics
Of the 33 participants enrolled in the study, 22 collected at least
10 swabs and were included in the study analysis. Eight
participants were diagnosed with BV by Amsel’s clinical criteria
at their initial visit, and 14 participants were not diagnosed with
BV. Subject characteristics are noted in Table 2. A total of 355
swabs were processed, including 192 swabs from healthy women
and 163 swabs from women with BV.
Comparison of self-collected and clinic-collected swabs
There was no significant difference in paired median levels of
human 18S rRNA gene copies, G. vaginalis or L. jensenii levels
(p.0.05) between clinic- and home-collected swabs. Median levels
of L. crispatus were higher in the clinic obtained swabs (p=0.02).
These data suggest that human and bacterial DNA levels were
largely similar in clinic- and home-collected swabs.
Variability in vaginal bacterial levels in women without
BV
Taxon-directed bacterial qPCR assays demonstrated that
healthy women were colonized with lactobacilli and typically did
not harbor BV-associated bacteria with the exception of G.
Vaginal Bacterial Dynamics
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common. Quantities of human 18S rRNA gene copies by qPCR
were relatively constant showing consistent loading of human cells
on the swabs with good stability of DNA and fluctuations in DNA
levels were not due to sample quality (Figure 1). An example of a
relatively stable vaginal microbiota is provided in Figure 1A,
where participant A is negative for BV at study entry. The
participant was colonized with L. crispatus and quantities remained
relatively stable throughout the period sampled. An increase of
.1-log G. vaginalis is observed at 3 weeks during menses. In
contrast, as demonstrated in Figure 1B, concentrations of
Lactobacillus species can fluctuate in participants without BV. A
4-log increase in G. vaginalis levels was observed along with an
increase in L. iners coincident with menses, and quantities
decreased without intervention at the end of menstruation.
Variability of Gardnerella vaginalis during menses
An increase in G. vaginalis levels associated with menses,
accompanied by decreased quantities of L. jensenii and L. crispatus
were observed (Figures 1 & 2). At the end of menstruation, G.
vaginalis quantities decreased to below detection limits (Figures 1 &
2) and L. iners concentrations declined as well (Figures 1B & 2B);
simultaneous increases in quantities of L. crispatus and L. jensenii
were observed. On average, quantities of L. crispatus were found to
be lower during menstruation by 0.6 logs (p=0.001) while G.
vaginalis quantities were found to be higher by 1.38 logs after
adjusting for sampling during treatment (Table 3). Quantities of L.
jensenii and L. crispatus were both found to be inversely related to G.
vaginalis; L. jensenii was lower by 0.19 logs per log10 increase in G.
vaginalis (p,0.001) and L. crispatus by 0.17 logs (p,0.001).
Eradication of BV-associated bacteria post antibiotic
treatment
With the exception of G. vaginalis, quantities of BV-associated
bacteria decreased several logs and dropped below detection
thresholds between Days 1 and 5 (Median=3.5 days) of
metronidazole treatment (Figure 3) in women with BV. We show
data from two representative subjects.
Participant E had high levels of BV-associated bacteria at
diagnosis which declined below detection thresholds (except G.
vaginalis), while concentrations of L. jensenii increased 3.5-logs. High
concentrations of L. iners were observed throughout the period
sampled.
In contrast, the rate of decrease of BV-associated bacteria in
Participant F was slower. Participant F maintained moderate to
high G. vaginalis levels throughout the period sampled. There were
transient increases in concentrations of some BV-associated
bacteria after eradication on Day 5, but they resolved by Day
15. However, an elevation of G. vaginalis, A. vaginae and Leptotrichia/
Sneathia spp. quantities were observed during menses. Participant F
was subsequently diagnosed with BV at her 1-month clinic visit.
Participant F was never colonized with L. crispatus or L. jensenii
throughout the period sampled.
Variability of bacteria in women with recurrent BV
Three women (37.5%) in this study had at least $2 episodes of
BV. Figure 4 shows recurrent BV in a representative participant
with three episodes of BV. Participant G harbored several BV-
associated bacteria and had a clinical diagnosis of BV at study
entry (Episode 1, Figure 4B). With treatment, quantities of BV-
Table 1. Primer and probe sequences used in the quantitative PCR assays developed in this study.
PCR Assay PCR Conditions Amplicon Size Primer/Probe Primer/Probe Sequence
Mobiluncus spp. 60uC annealing, 39 s 219 bp 805F_Mob 59-CCACGCTGTAAACGTTGGGAA-39
72uC extension, 30 s 1023R_Mob_curt 59-TGGCCCATCTCTGGAACCA-39
1024R_Mob_mul 59-CCACACCATCTCTGGCATG-39
Mob_838-861 59-FAM-ATGCTATCCTGTGTTTCTGCGCCGTAG-TAMRA-39
Lactobacillus iners 55uC annealing, 39 s 76 bp 165F_Liners 59-GATGCTAATACCGGATAAYAACAGAT-39
72uC extension, 30 s 241R_Liners 59-CACCGCAGGTCCATCCAAGA-39
Liners_186-213 59-FAM-TGCCTATCAACTGTTTAAAAGATGGTTCT-TAMRA-39
Lactobacillus jensenii 61uC annealing, 30 s 69 bp 988_Ljens 59-GTCTTGACATCCTTTGACCAC-39
72uC extension, 30 s 1057R_Ljens 59-CATGCACCACCTGTCTCTTT-39
Ljens_1009-1028 59-FAM-CTAAGAGATTAGGTTTTCCC-MGBNFQ-39
doi:10.1371/journal.pone.0010197.t001
Table 2. Demographic data of the women enrolled in the
longitudinal study.
Participant characteristic
Mean Age 31.3
Age Range 22–42
Median Age 30.5
1N( % )
Race
White 13 (59.1%)
African American
2 5 (22.7%)
Asian 2 (9.1%)
Did not answer 2 (9.1%)
Douching during the sampling period
3 1 (4.2%)
Other vaginal medication
3 3 (12.5%)
Vaginal product (not medication)
3 5 (20.8%)
Sexual activity
3 18 (75%)
1N indicates number of participants.
2Four of five participants reported another race.
3Data missing for 2 participants, hence the number of women included in the
calculation is 20, corresponding with 24 menstrual cycles captured. The
denominator used for the calculations is 24.
doi:10.1371/journal.pone.0010197.t002
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vaginalis). Subsequently, levels of BV-associated bacteria trended
upwards reaching maximal levels during menses. At the 1-month
clinic visit, Participant G was negative for BV by Amsel’s criteria
(pH 6, ,20% clue cells, negative whiff test, normal discharge) and
was not treated. Participant G returned to clinic 3 months later
and was diagnosed with BV (Episode 2, Figure 4C). With
metronidazole treatment, levels of BV-associated bacteria declined
below detection thresholds and the participant was clinically BV
negative at 1 month. However, she returned again in 3 months
and was diagnosed with the third episode of BV (Episode 3,
Figure 4D). With her third course of metronidazole, participant G
had a similar response as previously observed, wherein there was
initial decline of BV-associated bacteria and the participant was
clinically negative for BV at 1 month. However, two months later
quantities of G. vaginalis, Leptotrichia/Sneathia spp. and A. vaginae
increased but she did not return to clinic for further examination.
In all three episodes studied, L. iners had an inverse relationship
with the BV-associated bacteria. Participant G was never
colonized with L. jensenii and was briefly colonized with L. crispatus
through the sampling period.
Discussion
In our study of frequent sampling of the vaginal microbiota, we
found that the bacterial community is dynamic and changes
rapidly. We sought to study changes in the levels of bacteria in the
human vagina and assess their relationship with the common
condition, bacterial vaginosis. Our first goal was to determine how
stable the microbial community is in healthy women. As noted in
previous cultivation-based studies, healthy women tended to be
colonized with several Lactobacillus species, though G. vaginalis was
also frequently detected, including in 70% of women without BV
using PCR methods [12]. G. vaginalis concentrations increased
Figure 1. Variability of vaginal bacteria in women without BV. The line graphs show the changes in vaginal bacteria measured as 16S rRNA
gene copies per swab in a participant exhibiting a stable bacterial biota (A) and another with dynamic patterns (B). The red line indicates menses.
Clinical diagnosis was performed using Amsel’s criteria (green box in upper graph indicating negative for BV). Gram staining using the Nugent criteria
(the score is indicated as a number from 0–10 in the box) was also performed. A score of 0–3 indicates negative for BV, 4–6 reflects intermediate BV
flora and 7–10 denotes positive for BV. Levels of the human 18S rRNA gene (red circles) were used to assess the amount of vaginal fluid loaded on
each swab as reflected by human cell content. BVAB denotes bacterial vaginosis associated bacterium.
doi:10.1371/journal.pone.0010197.g001
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and levels decreased with the end of menstruation. During these
surges of G. vaginalis, L. iners levels also trended upwards while
levels of the other two lactobacilli decreased. Schwebke et al. [14]
have similarly reported increases in Gardnerella/Bacteroides morpho-
types by Gram stain and reduced quantities of lactobacilli during
menses. Our study enhances the observations made by these
authors by measuring levels of specific bacterial species and
provides the ability to distinguish among Lactobacillus species. In
our study, all subjects (n=14) classified as negative for BV by the
Amsel diagnostic criteria on Day 0 had at least a low level of G.
vaginalis on one of the days sampled. A longitudinal cultivation
study reported the isolation of G. vaginalis in at least one time point
in the menstrual cycle in all subjects, though the number of
subjects examined was small (n=7) [15]. These findings raise the
question of the role of the normal fluctuations of G. vaginalis in the
development of abnormal flora associated with BV.
The growth of G. vaginalis may be tied to the availability of iron.
Iron is an essential growth factor for most bacteria and the
Figure 2. Variability of Gardnerella vaginalis during menses. The line graphs show increases in G. vaginalis levels during menses while
concentrations of L. crispatus and L. jensenii decreased. G. vaginalis quantities declined below detection thresholds post-menses with simultaneous
increases in L. jensenii and L. crispatus levels. Participant C (Figure 2A) was not colonized with L. iners while Participant D (Figure 2B) was. Levels of L.
iners were observed to increase with G. vaginalis concentrations and subsequently declined post-menses. Both participants were negative for BV by
Amsel’s criteria (green boxes) and had Nugent scores of 0 at the entry and follow up visits.
doi:10.1371/journal.pone.0010197.g002
Table 3. Differences in levels of bacteria by qPCR during
menstruation.
Bacterium
mean log10 adjusted difference (95% CI),
p-value* during menstruation
Lactobacillus crispatus 20.60 (20.94, 20.25), p=0.001
Lactobacillus jensenii 20.39 (20.79, 0.01), p=0.06
Lactobacillus iners 0.10 (20.23, 0.43), p=0.56
Gardnerella vaginalis 1.38 (0.83, 1.93), p,0.001
Data shown for 16 subjects who reported days with and without menses during
the study period.
Mean log10 adjusted change, p-values, and 95% CIs (confidence intervals)
estimated using a linear mixed model with participants as random effects and
adjusted for treatment. We tested those patterns that appeared interesting
upon examination of the data; thus, these p-values and 95% CIs arise from
exploratory analyses and serve as a basis for future hypothesis-driven research.
doi:10.1371/journal.pone.0010197.t003
Vaginal Bacterial Dynamics
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[16,17,18]. There is limited free iron in the human body as much
of it is sequestered in compounds such as hemoglobin, the iron-
containing metalloprotein in erythrocytes, and lactoferrin, present
in mucosal tissues. One mechanism for acquiring iron is to lyse
host cells such as erythrocytes with a cytolysin thereby liberating
intracellular iron stores. G. vaginalis produces a toxin, vaginolysin, a
member of the cholesterol-dependent cytolysin family of toxins
[19,20]. Experiments examining the growth of G. vaginalis have
shown that this bacterium cannot grow in iron-limiting conditions,
but can use iron sources such as hemoglobin for growth and can
produce siderophores suggesting a well adapted ability to harvest
iron from the environment [21]. Our observation that surges in G.
vaginalis coincide with menses (and therefore vaginal blood) is
consistent with this hypothesis. As to the role of G. vaginalis in BV,
we hypothesize that G. vaginalis may function as a facilitator to
enhance acquisition of other BV-associated bacteria that are also
characteristic of this condition.
In healthy women, concentrations of L. iners, when present,
tended to increase along with levels of G. vaginalis during menses
(Figures 1 & 2). It is noteworthy that both G. vaginalis and L. iners
are easily cultivated on blood agar medium. As noted with
Participant G on multiple occasions, concentrations of L. iners
tended to increase with antibiotic treatment for BV, suggesting
that this bacterium may fill the niche vacated by the loss of BV-
associated bacteria.
Our second goal was to determine if BV-associated bacteria were
eradicated with antibiotic treatment in women with recurrent BV,
and to assess the time to eradication. We found that quantities of
BV-associated bacteria decreased rapidly with intravaginal metro-
nidazole, evidencing multi-log declines on a daily basis, though the
slopeofthisdeclinevaried(Figures3& 4).Thisobservationsupports
the hypothesis that recurrent BV is not a result of initial antibiotic
failure, but rather is associated with the reappearance of BV-
associated bacteria after completion of antibiotic therapy. We are
able to detect as few as 2.5 gene copies per qPCR reaction
translating to 375 16S rRNA copies per swab. Hence, if the bacteria
were present below these concentrations, we could not have
detected them. Understanding how women with recurrent BV
reacquire the BV bacteria is critical for prevention efforts.
Figure 3. Eradication of BV bacteria post-antibiotic treatment. Participant E (Figure 3A) and Participant F (Figure 3B) are two women with BV
by Amsel criteria (red boxes) and by Nugent criteria (Score=8) at study entry. There was a difference in the rate of decrease of BV bacteria post-
metronidazole therapy. Participant E was cured of BV at the 1 month visit as determined by Amsel’s (green box) and Nugent’s (Score=0) criteria.
Participant F was re-colonized with A. vaginae, Leptotrichia & Sneathia spp. and G. vaginalis; BV was diagnosed at that time. The green line at the
bottom of the graph shows days of metronidazole treatment and the red line denotes menses.
doi:10.1371/journal.pone.0010197.g003
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of subjects in this study. Longitudinal studies collecting many samples
require highly motivated participants. Some investigators have taken
the approach of processing limited numbers of samples from many
women [9,22,23,24,25]. Our approach was to process large numbers
ofsamplesfromarelativelysmallnumberofwomeninordertobetter
explore vaginal bacterial dynamics. Second, we applied 11 bacterial
assays; but thisdoesnot representallbacterialtaxa associated withthe
vagina. Complementary molecular technologies such as broad-range
PCR, cloning and sequencing, or pyrosequencing may help
overcome this limitation, though these approaches are not quanti-
tative. Third, although daily qPCR data were obtained from the
subjects, this was not correlated with daily clinical data such as exams
since the swabs were mostly self-collected. Fourth, all subjects were
from a single clinic and may not be broadly representative of
reproductive age women with and without BV. Fifth, patterns of
bacterial fluctuations were statistically examined in retrospect; hence
p-values and 95% CIs arise from exploratory analyses and serve as a
basis for future hypothesis-driven research.
In conclusion, the vagina is a dynamic microbial ecosystem
supporting a changing and diverse bacterial population, both in
healthy women and women with BV. Lactobacilli predominantly
occur in healthy women, although their Lactobacillus species profiles
vary. Subjects with BV have many fastidious BV-associated
bacteria that respond well to the 5-day metronidazole treatment
regimen, suggesting that these bacteria are susceptible to
metronidazole or are dependent on other bacteria that are
eradicated with antibiotic treatment. Recurrence of BV is
associated with reappearance of BV-associated bacteria suggesting
re-infection or resurgence from an endogenous reservoir. The rate
of decrease of the BV bacteria with antibiotic treatment varies,
suggesting that longer antibiotic treatments may be warranted in
some women.
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Figure 4. Bacterial fluctuations in a participant with recurrent BV. Figure 4A depicts dynamic patterns of BV bacteria in Participant G across a
period spanning 11 months. She was diagnosed with BV by Amsel’s and Nugent’s criteria at entry (Episode 1, 4B), and was responsive initially to
treatment. However, she had two more episodes subsequently (4C and 4D) and each time she responded to metronidazole treatment but had a
return of BV-associated bacteria and went on to develop BV.
doi:10.1371/journal.pone.0010197.g004
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